HIPAA-compliant · Same-day admissions available
Can Ozempic reduce alcohol cravings and help people control their drinking?
New Hope Health
Editorial Team
Can Ozempic reduce alcohol cravings and help people control their drinking? Emerging addiction science suggests the blockbuster drug semaglutide, commonly prescribed for type 2 diabetes and weight loss, may reduce alcohol consumption and heavy drinking days. Early clinical research comparing weekly injections with a placebo group has shown promising results, but important questions remain about safety, long-term effectiveness, and whether weight loss medications can help treat alcohol use disorder (AUD).
Ozempic (semaglutide) is a prescription medication in the glucagon-like peptide-1 (GLP-1) receptor agonist class, part of a broader group of glp 1 receptor agonists primarily used to treat type 2 diabetes. GLP-1 medications help regulate blood sugar, slows digestion, reduce appetite, and influence brain pathways involved in reward, motivation, and addictive behaviors. Recent research suggests these medications may also reduce alcohol cravings, alcohol consumption, and heavy drinking in people with alcohol use disorder (AUD). Researchers believe GLP-1 medications may reduce the brain's rewarding response to alcohol, potentially lowering the desire to drink. However, more research is needed to confirm their long-term safety and effectiveness, and Ozempic is not FDA-approved for alcohol addiction treatment.
Ozempic (semaglutide) activates GLP-1 receptors that regulate appetite, blood sugar, and brain pathways involved in reward and motivation. These pathways influence dopamine signaling, which plays a role in pleasure, cravings, and addictive behaviors. Researchers believe GLP-1 medications may reduce alcohol's rewarding effects, potentially lowering alcohol cravings and consumption. Alcohol stimulates the brain's reward system, reinforcing repeated drinking and increasing addiction risk. Ozempic may weaken this response and reduce heavy drinking, although its long-term effects on alcohol use disorder remain uncertain.
Emerging research suggests GLP-1 medications, including semaglutide, may reduce alcohol cravings and consumption. A small 2025 randomized clinical trial found that the lowest clinical doses of semaglutide reduced weekly alcohol craving, drinks per drinking day, and heavy drinking measures over nine weeks compared with placebo injections, but did not significantly reduce drinking frequency.
In a drinking lab, participants receiving semaglutide also consumed less alcohol, showing improvements across several drinking outcomes. Animal studies and observational research support these initial findings, but larger trials are needed to confirm long-term safety, effectiveness, and benefits for addiction treatment. Research led by a school of medicine found that semaglutide reduced average drinks and helped some participants experience fewer heavy drinking days, although researchers have not established whether the pill form produces the same effect.
Early research suggests Ozempic may offer several potential benefits for people with alcohol use disorder, although these effects are not yet established treatments.
Early research suggests low-dose semaglutide, a weight loss drug, may reduce heavy drinking, average drinks consumed, and breath alcohol concentration. A 2025 clinical trial found reductions in drinking quantity and heavy drinking measures compared with placebo, although long-term effects remain uncertain. In a drinking lab, researchers found that semaglutide reduced alcohol consumed, suggesting it may help delay drinking.
One study reported nearly 30% less alcohol consumption, with 40% of participants experiencing no heavy drinking days after treatment. These data suggest potential benefits, but larger studies are needed to confirm the findings. Both Ozempic and heavy alcohol use carry pancreatitis risks, and Ozempic is not FDA-approved for alcohol addiction treatment.
Some people report reduced alcohol cravings within weeks of starting GLP-1 medications, but no standard timeline has been established. A nine-week semaglutide trial found reductions in alcohol cravings and drinking behavior, although researchers have not determined exactly when these effects begin.
Results may vary based on dose, weekly drinking patterns, and individual health conditions. Patients should not increase or change their medication dosage to control alcohol cravings.
Alcohol use disorder (AUD) affects approximately 10.3% of Americans aged 12 and older, while excessive alcohol use contributes to about 178,000 preventable U.S. deaths annually and an estimated \$249 billion in economic costs. Binge drinking and alcohol-related conditions, including liver disease, cancer, and cardiovascular disease, remain public health concerns in Tennessee. Alcohol cravings are common during addiction and early recovery, especially with stress, anxiety, or depression. Research supported by the National Institute on Alcohol Abuse and Alcoholism suggests GLP-1 medications, often prescribed to lose weight, may help reduce heavy drinking days. Behavioral therapy, medication-assisted treatment, and outpatient addiction services can help Knoxville residents manage cravings and prevent relapse. Excessive alcohol use remains a leading cause of preventable death in the United States, highlighting the need for effective addiction treatment.
**Short-Term**:
**Long-Term**:
Alcohol use disorder frequently occurs alongside mental health disorders, including major depressive disorder, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), bipolar disorder, and social anxiety disorder. People may use alcohol to manage emotional distress, sleep problems, or traumatic memories, but repeated drinking can worsen symptoms and increase addiction risk. Alcohol can also interfere with psychiatric medications and make mental health treatment less effective.
Co-occurring disorders can create a cycle in which mental health symptoms increase alcohol cravings, while excessive drinking worsens depression, anxiety, and emotional stability. Integrated dual diagnosis treatment addresses both conditions through behavioral therapy, medication management, and relapse prevention.
Researchers are investigating whether GLP-1 medications, including semaglutide and liraglutide, may affect addiction involving alcohol, opioids, nicotine, cocaine, and cannabis. Early animal studies and limited human research suggest possible reductions in alcohol cravings and some substance-seeking behaviors, but evidence for treating opioid, stimulant, nicotine, or cannabis use disorders remains preliminary.
Researchers are also studying these drugs for smoking cessation, and in one small subgroup who smoked cigarettes at the start of a semaglutide trial, participants had significantly greater reductions in average cigarettes per day than those given placebo.
GLP-1 medications are also being studied for potential effects on depression, anxiety, and brain inflammation. However, they are not FDA-approved treatments for major depressive disorder, generalized anxiety disorder, PTSD, or substance use disorders, and their mental health benefits remain uncertain.
Research on Ozempic and alcohol addiction remains limited by small clinical trials, short study periods, and differences in participant health conditions. Many studies involve people with obesity defined by body mass index or type 2 diabetes, making broader conclusions difficult. More research is needed to determine appropriate dosing, long-term effectiveness, relapse prevention benefits, and whether cravings return after treatment, and larger, longer studies are still needed because participants were not actively seeking treatment in at least one trial.
No, Ozempic is not FDA-approved to treat alcohol use disorder, reduce alcohol cravings, or prevent relapse. The FDA has approved Ozempic for specific uses related to type 2 diabetes and associated health risks, while its potential role in addiction treatment remains under investigation.
Healthcare providers may prescribe medications off-label when medically appropriate, including for weight management, but that is distinct from treatment for alcohol use disorder and does not establish effectiveness for alcohol addiction. FDA-approved medications for alcohol use disorder include naltrexone, acamprosate, and disulfiram.
Ozempic acts on GLP-1 receptors involved in appetite regulation and brain reward pathways, while approved alcohol addiction medications target different aspects of alcohol dependence. Naltrexone reduces alcohol's rewarding effects and can help decrease heavy drinking, though it is often considered the gold standard and has limited effectiveness for many patients, while acamprosate supports abstinence after alcohol cessation. Disulfiram causes unpleasant physical reactions when alcohol is consumed, helping some patients avoid drinking.
Unlike Ozempic, these medications have established clinical evidence and FDA approval for alcohol use disorder. Treatment selection depends on drinking patterns, medical history, withdrawal risk, and individual recovery goals, and semaglutide and similar drugs remain investigational for AUD.
Alcohol cravings may return after stopping Ozempic, but researchers have not established how often this happens or how long any craving reduction lasts. Most clinical studies have focused on alcohol consumption during treatment rather than long-term outcomes after discontinuation.
People with alcohol use disorder may continue experiencing cravings due to stress, environmental triggers, or changes in mental health. Behavioral therapy, relapse prevention planning, and ongoing recovery support can help manage these challenges.
Behavioral therapies, including cognitive behavioral therapy (CBT), motivational interviewing, and relapse prevention counseling, help people identify triggers, manage cravings, and change drinking behaviors. Treatment can also address depression, anxiety, PTSD, and other co-occurring disorders.
Outpatient treatment and intensive outpatient programs (IOP) provide individual counseling, group therapy, and medication management while allowing patients to maintain daily responsibilities.
Seek professional help when alcohol cravings become difficult to control, drinking affects daily life, or attempts to quit are unsuccessful. Warning signs include binge drinking, increased tolerance, withdrawal symptoms, and worsening depression or anxiety. Alcohol withdrawal can cause serious complications, including seizures and delirium tremens. Severe confusion, hallucinations, or seizures require emergency medical attention.
Treatment depends on addiction severity, withdrawal risks, and co-occurring mental health conditions. Common options include:
Many private insurance plans, TennCare, and Medicare cover medically necessary alcohol addiction treatment. Benefits may include detox, residential care, outpatient programs, behavioral therapy, and medications. Coverage varies by plan, provider network, medical necessity, and authorization requirements. Patients should verify their benefits, deductibles, and copayments before starting treatment.
Research on Ozempic alcohol cravings suggests GLP-1 medications may help reduce alcohol intake, drinking quantity, and cravings for alcohol, potentially addressing an important treatment gap. However, initial findings do not establish these drugs as proven treatments for alcohol abuse or severe AUD. For adults in Knoxville, evidence-based addiction treatment, behavioral therapy, and ongoing recovery support remain essential for reducing cravings, preventing relapse, and avoiding the negative consequences of excessive drinking.
At New Hope Healthcare, as an in-network provider we work with most insurance plans, such as:
If you or a loved one are struggling with mental health challenges or substance abuse, seeking treatment and emotional support is crucial. Consulting a doctor can provide the necessary support and guidance for your teen. Reach out to New Hope Healthcare today. Our team of compassionate professionals is here to support your journey towards lasting well-being. Effective medication management is a crucial part of the treatment process to ensure safety and success. Give us a call at 866-799-0806.
Early research suggests Ozempic (semaglutide) may reduce alcohol cravings and heavy drinking in some people. However, it is not FDA-approved to treat alcohol use disorder.
Alcohol is not strictly prohibited with Ozempic, but drinking may worsen nausea, dehydration, and blood sugar problems. Patients should discuss alcohol use with their healthcare provider.
Alcohol cravings may return after stopping Ozempic, but research on long-term effects remains limited. Ongoing addiction treatment can help support relapse prevention.
Ozempic activates GLP-1 receptors involved in appetite and brain reward pathways. Researchers are studying whether these effects reduce alcohol cravings and drinking behavior.
Ozempic is not an approved treatment for alcohol addiction. Evidence-based options include behavioral therapy, counseling, and FDA-approved medications such as naltrexone, acamprosate, and disulfiram.
No. Ozempic does not treat alcohol withdrawal symptoms or prevent withdrawal seizures. People at risk of severe alcohol withdrawal may need medically supervised detoxification.
In This Article
Tags
Medication-assisted treatment (MAT) is an evidence-based treatment that combines FDA-approved medications with behavioral therapy and counseling to address opioid use disorder (OUD) and alcohol addiction.
You'll know what your space, device, and household need before your first Virtual IOP session, and what to do if a hard moment hits at home.
Staying sober during the holidays can be challenging, especially when Thanksgiving, Christmas, and New Year's bring family gatherings, social pressure, and changes to familiar routines.
Knowing how to talk to kids about addiction can be difficult for many parents, especially when alcohol or drug use affects a child's life.
Does insurance cover IOP for addiction and mental health treatment in Tennessee?
Loneliness and depression can have profound effects on mental and physical health, especially when feelings of loneliness develop into long-term social isolation.
New Hope Healthcare Institute offers confidential admissions support for addiction and mental health care—adults and teens—in Knoxville. Call or text 24/7. Verification is not a guarantee of coverage or admission.
